All In Biotech

Drug Trial Radar · NCT06727864

Short Course Regimen in Low Risk Active Tuberculosis- a Multicenter, Randomized, Active-controlled, Trial

Safety and Efficacy of Four-month Short Course Regimen in Low Risk Active Tuberculosis- a Multicenter Randomized Controlled Trial

Last checked: Nov 20, 2026Latest source record: Aug 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 270 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

270

Planned (sponsor's estimate)

Start

Jan 1, 2024

Primary completion

Dec 31, 2027

Study completion Dec 31, 2028

Sponsor

Lead sponsor
Kaohsiung Veterans General Hospital.Academic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Taipei Veterans General Hospital, Taiwan; National Taiwan University Hospital; Chang Gung Memorial Hospital; Far Eastern Memorial Hospital; E-DA Hospital; Kaohsiung Medical University
First posted
Dec 11, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 20 years, up to 99 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Tuberculosis remains an important global health problem, and the world is currently not on track to end the TB epidemic by 2030. With the concerted efforts of the government and medical community, the incidence of TB in Taiwan has gradually decreased, however, Taiwan remains an endemic area for TB. The development of efficacious, safe, and shorter treatment regimens could significantly improve treatment completion rate and reduce transmission of TB. The current treatment guidelines for drug-susceptible TB from the World Health Organization (WHO), American Thoracic Society (ATS), United States Center for Diseases Control (U.S. CDC), Infectious Diseases Society of America (IDSA) and European Respiratory Society (ERS) include 2 months of isoniazid, rifampin, pyrazinamide and ethambutol (HREZ), followed by 4 months of isoniazid, rifampin, and ethambutol(HRE). The current treatment regimen requires 6 months of treatment, despite being highly efficacious, requires long duration of treatment. Adherence to treatment is the major barrier which poses a negative impact to TB control, and increased cost to both the patient and the public health system. Developing an efficacious, safe and short treatment regimen can significantly improve TB management and treatment success rates.

Conditions

  • Pulmonary Tuberculosis

Interventions

  • 4-month regimen (2HERZ/2HRE)Drug

    4-month (2HERZ/2HRE)

  • 6-month (2HERZ/4HRE)Drug

    2 months of HREZ followed by 4 months of HR/HRE

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. TB disease free survival at 12 months post-randomizationTime frame: 12 months
  2. TB disease free survival at 24 months post randomizationTime frame: 24 months
  3. Grade 3-5 adverse eventsTime frame: From enrollment to the end of treatment at 4 or 6 months

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • Kaohsiung Medical University Chung-Ho Memorial Hospital

    Kaohsiung City, Taiwan · Recruiting

  • Kaohsiung Veterans General Hospital

    Kaohsiung City, Taiwan · Recruiting

  • Taipei Veterans General Hospital

    Taipei, Taiwan · Recruiting

  • National Taiwan University Hospital

    Taipei, Taiwan · Recruiting

  • Linkou Chang Gung Memorial Hospital

    Taoyuan City, Taiwan · Recruiting

  • Far Eastern Memorial Hospital

    New Taipei City, Bangiao, Taiwan · Recruiting

  • Taichung Hospital

    Taichung, West, Taiwan · Recruiting

  • E-DA Healthcare Group

    Kaohsiung City, Yanchao, Taiwan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.